PGEN Quote, Financials, Valuation and Earnings

Amneal Pharmaceuticals, Inc. has a net margin of -5008.35% compared to Precigen, Inc.'s net margin of 6.09%. Precigen, Inc.'s return on equity of -711.28% beat Amneal Pharmaceuticals, Inc.'s return on equity of -587.3%.

Precigen, Inc. has a consensus price target of $8.50, signalling upside risk potential of 124.27%. On the other hand Amneal Pharmaceuticals, Inc. has an analysts' consensus of $16.40 which suggests that it could grow by 10.07%. Given that Precigen, Inc. has higher upside potential than Amneal Pharmaceuticals, Inc., analysts believe Precigen, Inc. is more attractive than Amneal Pharmaceuticals, Inc..

Precigen, Inc. has a beta of 1.097, which suggesting that the stock is 9.675% more volatile than S&P 500. In comparison Amneal Pharmaceuticals, Inc. has a beta of 1.345, suggesting its more volatile than the S&P 500 by 34.51%.

Precigen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amneal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Precigen, Inc. pays -- of its earnings as a dividend. Amneal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Precigen, Inc. quarterly revenues are $2.9M, which are smaller than Amneal Pharmaceuticals, Inc. quarterly revenues of $814.3M. Precigen, Inc.'s net income of -$146.3M is lower than Amneal Pharmaceuticals, Inc.'s net income of $49.6M. Notably, Precigen, Inc.'s price-to-earnings ratio is -- while Amneal Pharmaceuticals, Inc.'s PE ratio is 62.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precigen, Inc. is 178.77x versus 1.49x for Amneal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Corcept Therapeutics, Inc. has a net margin of -5008.35% compared to Precigen, Inc.'s net margin of 11.83%. Precigen, Inc.'s return on equity of -711.28% beat Corcept Therapeutics, Inc.'s return on equity of 14.97%.

Precigen, Inc. has a consensus price target of $8.50, signalling upside risk potential of 124.27%. On the other hand Corcept Therapeutics, Inc. has an analysts' consensus of $65.40 which suggests that it could grow by 83.19%. Given that Precigen, Inc. has higher upside potential than Corcept Therapeutics, Inc., analysts believe Precigen, Inc. is more attractive than Corcept Therapeutics, Inc..

Precigen, Inc. has a beta of 1.097, which suggesting that the stock is 9.675% more volatile than S&P 500. In comparison Corcept Therapeutics, Inc. has a beta of 0.288, suggesting its less volatile than the S&P 500 by 71.236%.

Precigen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Precigen, Inc. pays -- of its earnings as a dividend. Corcept Therapeutics, Inc. pays out -- of its earnings as a dividend.

Precigen, Inc. quarterly revenues are $2.9M, which are smaller than Corcept Therapeutics, Inc. quarterly revenues of $202.1M. Precigen, Inc.'s net income of -$146.3M is lower than Corcept Therapeutics, Inc.'s net income of $23.9M. Notably, Precigen, Inc.'s price-to-earnings ratio is -- while Corcept Therapeutics, Inc.'s PE ratio is 43.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precigen, Inc. is 178.77x versus 5.62x for Corcept Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Marker Therapeutics, Inc. has a net margin of -5008.35% compared to Precigen, Inc.'s net margin of -162.11%. Precigen, Inc.'s return on equity of -711.28% beat Marker Therapeutics, Inc.'s return on equity of -103.04%.

Precigen, Inc. has a consensus price target of $8.50, signalling upside risk potential of 124.27%. On the other hand Marker Therapeutics, Inc. has an analysts' consensus of $7.87 which suggests that it could grow by 431.53%. Given that Marker Therapeutics, Inc. has higher upside potential than Precigen, Inc., analysts believe Marker Therapeutics, Inc. is more attractive than Precigen, Inc..

Precigen, Inc. has a beta of 1.097, which suggesting that the stock is 9.675% more volatile than S&P 500. In comparison Marker Therapeutics, Inc. has a beta of 1.419, suggesting its more volatile than the S&P 500 by 41.882%.

Precigen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Marker Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Precigen, Inc. pays -- of its earnings as a dividend. Marker Therapeutics, Inc. pays out -- of its earnings as a dividend.

Precigen, Inc. quarterly revenues are $2.9M, which are larger than Marker Therapeutics, Inc. quarterly revenues of $1.2M. Precigen, Inc.'s net income of -$146.3M is lower than Marker Therapeutics, Inc.'s net income of -$2M. Notably, Precigen, Inc.'s price-to-earnings ratio is -- while Marker Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precigen, Inc. is 178.77x versus 4.01x for Marker Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viridian Therapeutics, Inc. has a net margin of -5008.35% compared to Precigen, Inc.'s net margin of -77256.06%. Precigen, Inc.'s return on equity of -711.28% beat Viridian Therapeutics, Inc.'s return on equity of -53.74%.

Precigen, Inc. has a consensus price target of $8.50, signalling upside risk potential of 124.27%. On the other hand Viridian Therapeutics, Inc. has an analysts' consensus of $41.76 which suggests that it could grow by 41.95%. Given that Precigen, Inc. has higher upside potential than Viridian Therapeutics, Inc., analysts believe Precigen, Inc. is more attractive than Viridian Therapeutics, Inc..

Precigen, Inc. has a beta of 1.097, which suggesting that the stock is 9.675% more volatile than S&P 500. In comparison Viridian Therapeutics, Inc. has a beta of 0.998, suggesting its less volatile than the S&P 500 by 0.176%.

Precigen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viridian Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Precigen, Inc. pays -- of its earnings as a dividend. Viridian Therapeutics, Inc. pays out -- of its earnings as a dividend.

Precigen, Inc. quarterly revenues are $2.9M, which are larger than Viridian Therapeutics, Inc. quarterly revenues of $132K. Precigen, Inc.'s net income of -$146.3M is lower than Viridian Therapeutics, Inc.'s net income of -$102M. Notably, Precigen, Inc.'s price-to-earnings ratio is -- while Viridian Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precigen, Inc. is 178.77x versus 35.15x for Viridian Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.